Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial

INTRODUCTION: Few treatment options exist for patients with systemic lupus erythematosus (SLE) who fail conventional therapy. Although widely used to treat lupus, the efficacy of B cell depletion therapy using rituximab has not been demonstrated in randomised clinical trials. Following rituximab, el...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Alexis, Muller, Patrick, Dore, Caroline J, Ikeji, Felicia, Caverly, Emilia, Chowdhury, Kashfia, Isenberg, David A, Gordon, Caroline, Ehrenstein, Michael R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937022/
https://www.ncbi.nlm.nih.gov/pubmed/31848169
http://dx.doi.org/10.1136/bmjopen-2019-032569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937022/
https://www.ncbi.nlm.nih.gov/pubmed/31848169
http://dx.doi.org/10.1136/bmjopen-2019-032569

Ejemplares similares